Abstract: The present invention provides a chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to the neuroexcitatory amino acid glutamate and presents an advantageously high brain exposure upon oral administration, for the treatment or prevention of levodopa-induced dyskinesia. The present invention also provides an improved therapy of Parkinson's disease, using the chromone oxime derivative of formula (I) in combination with ievodopa.
Abstract: The present invention provides a novel chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to glutamate and, furthermore, presents an advantageously high brain penetration upon oral administration. The invention also relates to a pharmaceutical composition containing this compound, and to its use for the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions, or conditions which can be affected by alteration of glutamate level or signalling, particularly acute and chronic neurological and/or psychiatric disorders.
Type:
Grant
Filed:
June 5, 2018
Date of Patent:
October 15, 2019
Assignee:
Prexton Therapeutics SA
Inventors:
Delphine Charvin, Baptiste Manteau, Vincent Pomel, François Conquet
Abstract: The present invention provides a novel chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to glutamate and, furthermore, presents an advantageously high brain penetration upon oral administration. The invention also relates to a pharmaceutical composition containing this compound, and to its use for the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions, or conditions which can be affected by alteration of glutamate level or signalling, particularly acute and chronic neurological and/or psychiatric disorders.
Type:
Application
Filed:
June 5, 2018
Publication date:
October 11, 2018
Applicant:
Prexton Therapeutics SA
Inventors:
Delphine CHARVIN, Baptiste MANTEAU, Vincent POMEL, François CONQUET
Abstract: The present invention provides a novel chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to glutamate and, furthermore, presents an advantageously high brain penetration upon oral administration. The invention also relates to a pharmaceutical composition containing this compound, and to its use for the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions, or conditions which can be affected by alteration of glutamate level or signalling, particularly acute and chronic neurological and/or psychiatric disorders.
Type:
Grant
Filed:
August 27, 2015
Date of Patent:
July 10, 2018
Assignee:
Prexton Therapeutics SA
Inventors:
Delphine Charvin, Baptiste Manteau, Vincent Pomel, François Conquet